TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024
1. JOHNSON AND JOHNSON
Q1 REVENUES:
In the first quarter of 2024, Johnson & Johnson reported sales growth of 2.3%, reaching $21.4 billion. The operational growth was 3.9%, and the adjusted operational growth (excluding COVID-19 Vaccine impact) stood at 4.0%. Notably, adjusted operational growth, excluding the vaccine, was an impressive 7.7%.
Best selling drugs
2. ROCHE
Q1 RESULTS:
Sales Decline: In the first quarter of 2024, Roche reported a 6% decline in sales, amounting to 14.4 billion Swiss francs (approximately $15.80 billion). This decrease was attributed to the impact of foreign exchange rates and the loss of revenue from COVID-related products.
Pharmaceutical Division: The pharmaceutical division’s performance also slowed, with sales dropping to $11.96 billion from $12.71 billion in the same period last year.
3. PFIZER
Pfizer reported total revenues of $14.9 billion for Q1 2024.
Eliquis | $2.0 billion |
Paxlovid | $2.0 billion |
Ibrance | $1.0 billion |
4. ABBVIE
AbbVie delivered first-quarter net revenues of $12.310 billion, showing a modest increase of 0.7% on a reported basis and 1.6% on an operational basis.
Humira | $2.3 billion |
Skyrizi | $2.0 billion |
Rinvoq | $1.0 billion |
5. MERCK
Q1 RESULTS:
Merck reported continued strong growth in oncology and vaccines. Total worldwide sales for Q1 2024 were $14.0 billion.
Keytruda revenues were $6.9 billion, an increase of 20% revenues compared to previous year.
Keytruda | $14.0 billion |
Gardasil/Gardasil 9 | $2.2 billion |
6. SANOFI
Q1 REVENUES
Sanofi achieved a 6.7% sales growth at constant exchange rates (CER), with net sales totaling $12.4 billion. Dupixent revenues were $3.4 billion, and expected revenues were $14.0 billion.
7. NOVARTIS
Sales Growth: The company reported a 25% increase in net income from continuing operations, reaching $2.68 billion compared to $2.15 billion in Q1 2023.
8. ASTRAZENECA
9. BMS
In the first quarter, Bristol Myers Squibb reported revenues of $11.9 billion, marking a 5% increase, or 6% when accounting for foreign exchange effects. This growth was primarily fueled by strong performances from Eliquis, Reblozyl, and Opdualag, although somewhat tempered by declines in Opdivo and Revlimid sales.
In the U.S., revenues rose by 7% to $8.5 billion, driven by the success of Eliquis, Reblozyl, and Opdualag, offsetting declines in Revlimid. Opdivo revenues saw a decrease from $1.3 billion to $1.2 billion, down by 10%, mainly due to inventory adjustments and timing of orders, despite underlying demand growth.
Meanwhile, international revenues remained relatively steady at $3.4 billion, as increased demand for Opdivo, Yervoy, and Reblozyl offset lower selling prices. Foreign exchange fluctuations had a 5% adverse impact on revenues.
10. ABBOTT